由于免疫抑制治疗，实体器官移植受者患皮肤癌的风险增加。然而，人们对心脏移植受者（HTR）肿瘤的风险和特征知之甚少。本研究的目的是描绘 HTR 中不同皮肤肿瘤的发病率，并将其与其他恶性肿瘤（包括实体瘤和血液肿瘤）的发病率相关联。 检索 1991 年 1 月至 2021 年 11 月期间接受 HTR 的患者。获得了免疫抑制治疗、皮肤肿瘤、实体瘤和血液肿瘤的临床数据。患有皮肤肿瘤的 HTR 被纳入 A 组，而随访期间没有皮肤肿瘤证据的患者被纳入 B 组。共回收 108 名患者。 A组实体瘤显着增加，而血液肿瘤在两组之间没有检测到显着差异。具有皮肤肿瘤的HTR表现出实体瘤发生率显着更高。在大多数情况下，皮肤肿瘤先于实体瘤发生，这表明皮肤肿瘤可能代表免疫抑制的“标志物”，最终导致内部恶性肿瘤的发展。

Solid organ transplant recipients are at increased risk for skin cancers due to immune-suppressive therapies. However, little is known about the risk and the characteristics of neoplasms in heart transplant recipients (HTRs). The aim of this study is to delineate the incidence of different skin tumors in HTRs and to correlate it with the incidence of other malignancies, including solid tumors and hematological neoplasms.Patients who underwent to HTRs between January 1991 and November 2021 were retrieved. Clinical data on immunosuppressive therapies, skin tumors, solid and hematological neoplasms were obtained. HTRs with skin tumors were included in group A, while patients with no evidence of skin tumors during the follow-up were included in group B.One hundred and eight patients were retrieved. A significant increase in solid tumors was observed in group A, while no significant difference in hematological neoplasms was detected between the two groups.HTRs with skin tumors showed a significantly higher incidence of solid neoplasms. In most of the cases the skin tumor preceded the onset of the solid neoplasm, suggesting that the skin tumor could represent a 'marker' of immunosuppression eventually leading to the development of an internal malignancy.